PE20130314A1 - PORCIONES DE ENLACE A ANTI-C5a CON ALTA ACTIVIDAD DE BLOQUEO - Google Patents
PORCIONES DE ENLACE A ANTI-C5a CON ALTA ACTIVIDAD DE BLOQUEOInfo
- Publication number
- PE20130314A1 PE20130314A1 PE2012000715A PE2012000715A PE20130314A1 PE 20130314 A1 PE20130314 A1 PE 20130314A1 PE 2012000715 A PE2012000715 A PE 2012000715A PE 2012000715 A PE2012000715 A PE 2012000715A PE 20130314 A1 PE20130314 A1 PE 20130314A1
- Authority
- PE
- Peru
- Prior art keywords
- link
- seq
- portions
- blocking activity
- high blocking
- Prior art date
Links
- 230000000903 blocking effect Effects 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 108091034117 Oligonucleotide Proteins 0.000 abstract 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 abstract 1
- 239000013543 active substance Substances 0.000 abstract 1
- 230000001154 acute effect Effects 0.000 abstract 1
- 150000001413 amino acids Chemical group 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/14—Peptides, e.g. proteins
- A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Biotechnology (AREA)
- Radiology & Medical Imaging (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Vascular Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
Abstract
SE REFIERE A UNA PORCION DE ENLACE QUE SE ENLAZA A UN EPITOPO CONFORMACIONAL DE C5a SELECCIONADO DE LA SIGUIENTES SECUENCIAS DE AMINOACIDOS: SEQ ID Nº 18, SEQ ID Nº 19, SEQ ID Nº 4, SEQ ID Nº 38, SEQ ID Nº 39, ENTRE OTROS, DONDE DICHA PORCION DE ENLACE SE SELECCIONA DEL GRUPO QUE CONSISTE DE ANTICUERPOS O FRAGMENTOS DE ENLACE A ANTIGENOS, OLIGONUCLEOTIDOS, PROTEINAS SIMILARES A ANTICUERPO PEPTIDOMETICOS. REFERIDA ADEMAS A UNA COMPOSICION FARMACEUTICA. DICHA PORCION DE ENLACE ES UTIL COMO AGENTE ACTIVO EN UNA COMPOSICION FARMACEUTICA PARA EL TRATAMIENTO Y/O PREVENCION DE ENFERMEDADES INFLAMATORIAS AGUDAS
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26469609P | 2009-11-26 | 2009-11-26 | |
| EP09014745A EP2327725A1 (en) | 2009-11-26 | 2009-11-26 | Anti-C5a binding moieties with high blocking activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20130314A1 true PE20130314A1 (es) | 2013-04-03 |
Family
ID=41683202
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2012000715A PE20130314A1 (es) | 2009-11-26 | 2010-11-26 | PORCIONES DE ENLACE A ANTI-C5a CON ALTA ACTIVIDAD DE BLOQUEO |
Country Status (29)
| Country | Link |
|---|---|
| US (4) | US8802096B2 (es) |
| EP (4) | EP2327725A1 (es) |
| JP (4) | JP6104605B2 (es) |
| KR (3) | KR101844611B1 (es) |
| CN (2) | CN105037541A (es) |
| AU (1) | AU2010324141B2 (es) |
| BR (1) | BR112012012514B1 (es) |
| CA (1) | CA2780520C (es) |
| CL (1) | CL2012001304A1 (es) |
| CY (2) | CY1118463T1 (es) |
| DK (2) | DK2504362T3 (es) |
| EA (1) | EA022759B1 (es) |
| ES (2) | ES2613352T3 (es) |
| FR (1) | FR25C1024I1 (es) |
| HR (2) | HRP20170041T1 (es) |
| HU (2) | HUE032543T2 (es) |
| IL (1) | IL219911A (es) |
| LT (2) | LT3181582T (es) |
| MX (1) | MX2012006060A (es) |
| NL (1) | NL301334I2 (es) |
| NZ (1) | NZ600348A (es) |
| PE (1) | PE20130314A1 (es) |
| PH (1) | PH12012501243A1 (es) |
| PL (2) | PL2504362T3 (es) |
| PT (2) | PT2504362T (es) |
| RS (2) | RS59955B1 (es) |
| SI (2) | SI3181582T1 (es) |
| SM (3) | SMT201700054T1 (es) |
| WO (1) | WO2011063980A1 (es) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101479381B (zh) | 2006-03-31 | 2015-04-29 | 中外制药株式会社 | 调控抗体血液动力学的方法 |
| EP3127921A1 (en) | 2007-09-26 | 2017-02-08 | Chugai Seiyaku Kabushiki Kaisha | Method of modifying isoelectric point of antibody via amino acid substition in cdr |
| HUE067049T2 (hu) | 2008-04-11 | 2024-09-28 | Chugai Pharmaceutical Co Ltd | Két vagy több antigén-molekulát ismétlõdõen megkötni képes antigénkötõ molekula |
| US8703129B2 (en) | 2008-09-07 | 2014-04-22 | GlycoNex, Inc. | Antibodies against extended type 1 chain antigens, derivatives thereof and use |
| EP2327725A1 (en) | 2009-11-26 | 2011-06-01 | InflaRx GmbH | Anti-C5a binding moieties with high blocking activity |
| WO2011137395A1 (en) | 2010-04-30 | 2011-11-03 | Rother Russell P | Anti-c5a antibodies and methods for using the antibodies |
| CN103328632A (zh) | 2010-11-30 | 2013-09-25 | 中外制药株式会社 | 与多分子的抗原重复结合的抗原结合分子 |
| MX379206B (es) | 2011-06-22 | 2025-03-10 | Apellis Pharmaceuticals Inc | Uso de inhibidores del complemento en trastornos crónicos. |
| MY167232A (en) * | 2012-02-20 | 2018-08-14 | Swedish Orphan Biovitrum Ab Publ | Polypeptides binding to human complement c5 |
| EP2666785A1 (en) * | 2012-05-23 | 2013-11-27 | Affiris AG | Complement component C5a-based vaccine |
| MY173804A (en) | 2013-08-28 | 2020-02-24 | Swedish Orphan Biovitrum Ab Publ | Stable polypeptides binding to human complement c5 |
| PL3039033T3 (pl) | 2013-08-28 | 2020-01-31 | Affibody Ab | Polipeptydy wiążące o zmutowanym rusztowaniu |
| US9603927B2 (en) * | 2014-02-28 | 2017-03-28 | Janssen Biotech, Inc. | Combination therapies with anti-CD38 antibodies |
| US9732154B2 (en) | 2014-02-28 | 2017-08-15 | Janssen Biotech, Inc. | Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia |
| CA2940319A1 (en) | 2014-03-20 | 2015-09-24 | Inflarx Gmbh | Inhibitors of c5a for the treatment of viral pneumonia |
| US20160067205A1 (en) | 2014-09-09 | 2016-03-10 | Janssen Biotech, Inc. | Combination Therapies with Anti-CD38 Antibodies |
| HK1247221A1 (zh) | 2014-12-04 | 2018-09-21 | Janssen Biotech, Inc. | 用於治疗急性髓系白血病的抗cd38抗体 |
| TWI779010B (zh) | 2014-12-19 | 2022-10-01 | 日商中外製藥股份有限公司 | 抗肌抑素之抗體、含變異Ｆｃ區域之多胜肽及使用方法 |
| AR103162A1 (es) | 2014-12-19 | 2017-04-19 | Chugai Pharmaceutical Co Ltd | Anticuerpos anti-c5 y métodos para su uso |
| HK1253242A1 (zh) | 2015-05-20 | 2019-06-14 | Janssen Biotech, Inc. | 用於治疗轻链淀粉样变性及其它cd38阳性血液恶性肿瘤的抗cd38抗体 |
| CA2990406A1 (en) | 2015-06-22 | 2016-12-29 | Janssen Biotech, Inc. | Combination therapies for heme malignancies with anti-cd38 antibodies and survivin inhibitors |
| US20170044265A1 (en) | 2015-06-24 | 2017-02-16 | Janssen Biotech, Inc. | Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38 |
| AU2016350717B2 (en) | 2015-11-03 | 2023-08-10 | Janssen Biotech, Inc. | Subcutaneous formulations of anti-CD38 antibodies and their uses |
| US10781261B2 (en) | 2015-11-03 | 2020-09-22 | Janssen Biotech, Inc. | Subcutaneous formulations of anti-CD38 antibodies and their uses |
| CN106957366B (zh) * | 2016-01-12 | 2022-02-01 | 上海昀怡健康科技发展有限公司 | 一种C5aR抗体及其制备方法和应用 |
| EP3454902A4 (en) * | 2016-05-10 | 2019-10-09 | Annexon, Inc. | ANTI-COMPLEMENT FACTOR C4 / C4B ANTIBODIES AND USES THEREOF |
| EP3468990B1 (en) | 2016-06-14 | 2024-03-27 | Regeneron Pharmaceuticals, Inc. | Anti-c5 antibodies and uses thereof |
| JP2019527678A (ja) | 2016-06-28 | 2019-10-03 | ユーエムセー・ユトレヒト・ホールディング・ベー・フェー | ＣＤ３８に特異的に結合する抗体によるＩｇＥ媒介疾患の治療 |
| JP6527643B2 (ja) | 2016-08-05 | 2019-06-05 | 中外製薬株式会社 | Ｉｌ−８関連疾患の治療用又は予防用組成物 |
| AU2018230657A1 (en) * | 2017-03-06 | 2019-09-26 | The Trustees Of The University Of Pennsylvania | Anti-C5 antibodies and uses thereof |
| US11274146B2 (en) * | 2017-03-23 | 2022-03-15 | The Trustees Of The University Of Pennsylvania | Anti-C5a antibodies and uses thereof |
| EP3411400B1 (en) | 2017-04-03 | 2021-09-22 | InflaRx GmbH | Treatment of inflammatory diseases with inhibitors of c5a activity |
| US10376595B2 (en) | 2017-04-03 | 2019-08-13 | Inflarx Gmbh | Treatment of inflammatory diseases with inhibitors of C5a activity |
| KR20200020727A (ko) | 2017-06-23 | 2020-02-26 | 인플라알엑스 게엠베하 | C5a 활성의 억제제를 사용한 염증 질병의 치료 |
| KR20200079293A (ko) | 2017-10-31 | 2020-07-02 | 얀센 바이오테크 인코포레이티드 | 고위험 다발성 골수종을 치료하는 방법 |
| SG11202004662RA (en) | 2017-12-13 | 2020-06-29 | Regeneron Pharma | Anti-c5 antibody combinations and uses thereof |
| EP3586865A1 (en) | 2018-06-21 | 2020-01-01 | Charité - Universitätsmedizin Berlin | Complement anaphylatoxin binders and their use in treatment of a subject having an ocular wound and/or fibrosis |
| CN109053882B (zh) * | 2018-08-28 | 2019-08-23 | 东莞市朋志生物科技有限公司 | 一种ns1蛋白的结合蛋白以及应用 |
| KR20210055742A (ko) | 2018-09-06 | 2021-05-17 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 인간화된 항-c5 항체 및 이의 용도 |
| TWI869528B (zh) | 2020-01-13 | 2025-01-11 | 美商威特拉公司 | C5ar1抗體分子及其用途 |
| US20230158060A1 (en) * | 2020-03-27 | 2023-05-25 | Inflarx Gmbh | Inhibitors of C5a for the Treatment of Corona Virus Infection |
| TW202208427A (zh) | 2020-05-06 | 2022-03-01 | 德商因夫萊亞斯有限公司 | 人源化抗ｃ５ａ抗體 |
| CA3183886A1 (en) | 2020-06-24 | 2021-12-30 | Pingxia ZHU | Antibodies specifically recognizing c5a and uses thereof |
| WO2022155340A1 (en) | 2021-01-13 | 2022-07-21 | Visterra, Inc. | Humanized complement 5a receptor 1 antibodies and methods of use thereof |
| WO2023050233A1 (en) * | 2021-09-29 | 2023-04-06 | The Trustees Of The University Of Pennsylvania | Humanized anti-c5a antibodies and uses thereof |
| WO2023116574A1 (zh) * | 2021-12-22 | 2023-06-29 | 舒泰神（北京）生物制药股份有限公司 | 一种分离的抗C5a抗体及其制剂与应用 |
| WO2023186054A1 (zh) * | 2022-04-02 | 2023-10-05 | 舒泰神（北京）生物制药股份有限公司 | 特异性识别c5a的抗体及其应用 |
| WO2024245527A1 (en) | 2023-05-26 | 2024-12-05 | Inflarx Gmbh | Treatment of pneumonia and ards with inhibitors of c5a and il-6 activity |
| US12180274B2 (en) | 2023-05-26 | 2024-12-31 | Inflarx Gmbh | Treatment of pneumonia and ARDS with inhibitors of C5a and IL-6 activity |
| TW202535938A (zh) | 2023-10-17 | 2025-09-16 | 德商拜恩迪克公司 | 專一性結合ｃｄ３之抗原結合蛋白及其醫藥用途 |
| WO2025082594A1 (en) | 2023-10-17 | 2025-04-24 | BioNTech SE | Antigen binding proteins specifically binding to cd3 and their use in medicine |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4704355A (en) | 1985-03-27 | 1987-11-03 | New Horizons Diagnostics Corporation | Assay utilizing ATP encapsulated within liposome particles |
| WO1988007089A1 (en) | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
| WO1991004014A1 (en) | 1989-09-21 | 1991-04-04 | Synergen, Inc. | Method for transporting compositions across the blood brain barrier |
| ES2284161T3 (es) | 1990-01-12 | 2007-11-01 | Amgen Fremont Inc. | Generacion de anticuerpos xenogenicos. |
| US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| US6673346B1 (en) * | 1999-08-31 | 2004-01-06 | The Regents Of The University Of Michigan | Compositions and methods for the treatment of sepsis |
| US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| US7432356B2 (en) * | 2001-08-17 | 2008-10-07 | Genentech, Inc. | Complement pathway inhibitors binding to C5 and C5a without preventing formation of C5b |
| EP1878441B1 (en) * | 2001-08-17 | 2018-01-24 | Genentech, Inc. | Complement pathway inhibitors binding to C5 and C5a without preventing the formation of C5b |
| WO2003074679A2 (en) * | 2002-03-01 | 2003-09-12 | Xencor | Antibody optimization |
| WO2003086458A1 (en) * | 2002-04-12 | 2003-10-23 | Medimmune, Inc. | Recombinant anti-interleukin-9 antibodies |
| EP2327725A1 (en) * | 2009-11-26 | 2011-06-01 | InflaRx GmbH | Anti-C5a binding moieties with high blocking activity |
| WO2011137395A1 (en) | 2010-04-30 | 2011-11-03 | Rother Russell P | Anti-c5a antibodies and methods for using the antibodies |
-
2009
- 2009-11-26 EP EP09014745A patent/EP2327725A1/en not_active Withdrawn
-
2010
- 2010-11-26 AU AU2010324141A patent/AU2010324141B2/en active Active
- 2010-11-26 SM SM20170054T patent/SMT201700054T1/it unknown
- 2010-11-26 PE PE2012000715A patent/PE20130314A1/es active IP Right Grant
- 2010-11-26 BR BR112012012514-1A patent/BR112012012514B1/pt active IP Right Grant
- 2010-11-26 KR KR1020127016454A patent/KR101844611B1/ko active Active
- 2010-11-26 HR HRP20170041TT patent/HRP20170041T1/hr unknown
- 2010-11-26 DK DK10782561.4T patent/DK2504362T3/en active
- 2010-11-26 SI SI201031978T patent/SI3181582T1/sl unknown
- 2010-11-26 SM SM20200106T patent/SMT202000106T1/it unknown
- 2010-11-26 EP EP20153768.5A patent/EP3670532A1/en not_active Withdrawn
- 2010-11-26 NZ NZ600348A patent/NZ600348A/en unknown
- 2010-11-26 ES ES10782561.4T patent/ES2613352T3/es active Active
- 2010-11-26 JP JP2012540323A patent/JP6104605B2/ja active Active
- 2010-11-26 KR KR1020197009756A patent/KR102112969B1/ko active Active
- 2010-11-26 LT LTEP16199344.9T patent/LT3181582T/lt unknown
- 2010-11-26 PL PL10782561T patent/PL2504362T3/pl unknown
- 2010-11-26 US US13/512,334 patent/US8802096B2/en active Active
- 2010-11-26 EP EP10782561.4A patent/EP2504362B1/en active Active
- 2010-11-26 HU HUE10782561A patent/HUE032543T2/en unknown
- 2010-11-26 ES ES16199344T patent/ES2773725T3/es active Active
- 2010-11-26 EP EP16199344.9A patent/EP3181582B1/en active Active
- 2010-11-26 DK DK16199344.9T patent/DK3181582T3/da active
- 2010-11-26 MX MX2012006060A patent/MX2012006060A/es active IP Right Grant
- 2010-11-26 RS RS20200194A patent/RS59955B1/sr unknown
- 2010-11-26 WO PCT/EP2010/007197 patent/WO2011063980A1/en not_active Ceased
- 2010-11-26 KR KR1020187008236A patent/KR20180034690A/ko not_active Ceased
- 2010-11-26 CN CN201510333262.4A patent/CN105037541A/zh active Pending
- 2010-11-26 RS RS20170025A patent/RS55571B1/sr unknown
- 2010-11-26 SI SI201031368A patent/SI2504362T1/sl unknown
- 2010-11-26 CA CA2780520A patent/CA2780520C/en active Active
- 2010-11-26 EA EA201200795A patent/EA022759B1/ru unknown
- 2010-11-26 PT PT107825614T patent/PT2504362T/pt unknown
- 2010-11-26 LT LTEP10782561.4T patent/LT2504362T/lt unknown
- 2010-11-26 PT PT161993449T patent/PT3181582T/pt unknown
- 2010-11-26 HU HUE16199344A patent/HUE049376T2/hu unknown
- 2010-11-26 PH PH1/2012/501243A patent/PH12012501243A1/en unknown
- 2010-11-26 CN CN201080062363.8A patent/CN102741283B/zh active Active
- 2010-11-26 PL PL16199344T patent/PL3181582T3/pl unknown
-
2012
- 2012-05-18 CL CL2012001304A patent/CL2012001304A1/es unknown
- 2012-05-21 IL IL219911A patent/IL219911A/en active IP Right Grant
-
2014
- 2014-06-27 US US14/317,968 patent/US9073983B2/en active Active
-
2015
- 2015-06-03 US US14/729,865 patent/US9458233B2/en active Active
- 2015-12-02 JP JP2015235562A patent/JP6591272B2/ja active Active
-
2016
- 2016-09-16 US US15/267,902 patent/US10774136B2/en active Active
-
2017
- 2017-01-12 CY CY20171100048T patent/CY1118463T1/el unknown
- 2017-01-24 SM SM201700054T patent/SMT201700054B/it unknown
- 2017-11-27 JP JP2017226849A patent/JP2018080170A/ja active Pending
-
2019
- 2019-04-16 JP JP2019077667A patent/JP2019163266A/ja active Pending
-
2020
- 2020-02-12 HR HRP20200241TT patent/HRP20200241T1/hr unknown
- 2020-02-19 CY CY20201100151T patent/CY1122674T1/el unknown
-
2025
- 2025-06-25 FR FR25C1024C patent/FR25C1024I1/fr active Active
- 2025-07-09 NL NL301334C patent/NL301334I2/nl unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20130314A1 (es) | PORCIONES DE ENLACE A ANTI-C5a CON ALTA ACTIVIDAD DE BLOQUEO | |
| CL2018000537A1 (es) | Anticuerpo anti-factor d del complemento; polinucleótido codificante; vector que comprende dicho polinucleótido; célula húesped que comprende dicho vector; método de fabricación de anticuerpo; composición farmacéutica que lo comprende; uso del anticuerpo para tratar trastornos inflamatorios o trastornos oculares (divisional de cl 1001-2009). | |
| AR107020A2 (es) | Vacuna de pcsk9 (proteína convertasa subtilisina-kexina tipo 9) | |
| MX2015005328A (es) | Composiciones y metodos para la administracion selectiva de moleculas de oligonucleotidos a tipos de celulas. | |
| PE20230404A1 (es) | Un conjugado que comprende oxintomodulina y un fragmento de inmunoglobulina, y uso del mismo | |
| ITMI20021527A1 (it) | Anticorpi anti componente c5 del complemento e loro uso | |
| MX351975B (es) | Composiciones y metodos para el tratamiento de infecciones y tumores. | |
| AR084939A1 (es) | Composiciones farmaceuticas que comprenden anticuerpos humanos frente a pcsk9, formas de dosificacion unitarias, articulo manufacturado, metodo | |
| BR112012018947B1 (pt) | anticorpo anti-caprin-1 monoclonal, composição farmacêutica, combinação farmacêutica e usos de uma composição farmacêutica, de um anticorpo e de uma combinação farmacêutica | |
| BR112014021102A2 (pt) | Anticorpo, composição farmacêutica, droga de combinação, dna, método de tratamento e uso de anticorpo | |
| MX2015009963A (es) | Metodos y composición farmacéutica para el tratamiento y la prevención de cardiomiopatía debido a falta de energía. | |
| BR112012012918A8 (pt) | Agente indutor de apoptose para o tratamento de câncer e de doenças imunes e autoimunes | |
| BR112017018383A2 (pt) | inclusão de éxon2 induzida por anti-sentido em alfa-glucosidase ácida | |
| MX2019000547A (es) | Formulaciones de adamts13 liquidas y liofilizadas, estabilizadas. | |
| MX2018013517A (es) | Anticuerpos anti-il-1r3 humanizados. | |
| EA201591590A1 (ru) | Модифицированные олигонуклеотиды трф-бета | |
| MX348526B (es) | Composiciones orgánicas para tratar las enfermedades relacionadas con hsf1. | |
| PE20131065A1 (es) | Composiciones farmaceuticas combinadas y metodo de tratamiento del vertigo, la cinetosis y la distonia vegetativa-vascular | |
| AR082312A1 (es) | Una composicion farmaceutica de combinacion para tratar diabetes y desordenes metabolicos | |
| RU2013126581A (ru) | Мутанты стрептокиназы и их ковалентно модифицированные формы | |
| WO2011038933A3 (en) | Anti-hsv antibody | |
| MX2017010763A (es) | Nuevo anticuerpo que se una a tfpi y composicion que comprende el mismo. | |
| PE20130387A1 (es) | Composicion farmaceutica y combinacion y metodos para tratar las enfermedades o las condiciones asociadas con la enfermedad o condicion respiratoria | |
| UY35250A (es) | Anticuerpos anti-lamp1 y conjugados anticuerpo fármaco, y usos de éstos. | |
| WO2011053789A3 (en) | Pharmaceutical composition and methods to enhance cytotoxic t-cell recognition and maintain t-cell memory against a pathogenic disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |